Adial Becomes Azora Therapeutics; New CEO and CFO Named; Authorized Shares Raised to 500M
ADIL has more than doubled off its 52-week low of $1.31.
Summary
Adial completed its rebrand to Azora Therapeutics with a new CEO, CFO and CSO, and stockholders approved a charter amendment raising authorized common shares from 100 million to 500 million. The Series A preferred conversion and warrant authorizations clear the way for the merged company to advance AT177 into a Phase 1 trial in 2027.
Key Events · Executive and Board Changes · ADIL
-
Name Change and Ticker to AZR
A charter amendment renames the company Azora Therapeutics, Inc., effective 12:01 AM October 29, 2026; trading moves to Nasdaq symbol AZR with new CUSIP 054800107.
-
Authorized Shares Raised to 500M
Stockholders approved increasing authorized common stock from 100,000,000 to 500,000,000 shares, creating substantial capacity for future issuance.
-
Preferred Conversion and Warrant Issuance Approved
Proposals 3-6 approved issuance of 12,930,601 shares on Series A preferred conversion, 1,177,782 shares on assumed option exercises, 11,780,948 pre-funded warrant shares and 23,561,896 milestone warrant shares.
-
New CEO, CFO and CSO Installed
Matthew Davidson became President and CEO, Celia Economides CFO and Julie Saiki Chief Strategy Officer; Cary Claiborne and Vinay Shah were terminated effective the same date.
Analysis · ADIL · Life Sciences
The final steps of the Azora reverse merger are now complete. Stockholders approved converting the Series A preferred into 12,930,601 common shares and authorized warrant exercises totaling roughly 36.5 million more shares, while the charter now permits 500 million common shares versus 100 million before. That headroom is the raw material for future dilution, though no new shares were sold in this filing. The bigger near-term read is governance: a new CEO (Davidson), CFO (Economides) and Chief Strategy Officer (Saiki) take over, with the prior CEO and CFO terminated. Management says the ~$32 million raised alongside the June merger funds operations into 2028, with a Phase 1 trial of AT177 in ulcerative colitis expected in the first half of 2027.
How filings like this one have moved
In the 30 days to Oct 28, 2026, 30.7% of the 1698 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ADIL was trading at $4.86 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.3M. The 52-week trading range was $1.31 to $9.53. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.